Go Pro
→ Elon Musk’s Hushed FCC Filing. Sept 25th. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$2.23
-5.1%		$3.30
$2.23
▼
$13.40
$1.46M1.121.08 million shs183,186 shs
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$2.23
+1.4%		$72.96
$2.06
▼
$83,758.80
$1.07M1.851.83 million shs46,901 shs
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
$0.01
$0.01
$0.01
▼
$0.02
$389K1.06170,900 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.00%-34.41%-37.36%-27.83%-83.15%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.00%-25.67%-48.28%-98.06%-99.99%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$0.60
$0.60
$0.48
▼
$25.44
$1.23M1.4122,322 shsN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$2.23
-5.1%		$3.30
$2.23
▼
$13.40
$1.46M1.121.08 million shs183,186 shs
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$2.23
+1.4%		$72.96
$2.06
▼
$83,758.80
$1.07M1.851.83 million shs46,901 shs
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
$0.01
$0.01
$0.01
▼
$0.02
$389K1.06170,900 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.00%-34.41%-37.36%-27.83%-83.15%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.00%-25.67%-48.28%-98.06%-99.99%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
0.00
N/AN/AN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.001,873.09% Upside
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
1.00
SellN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VIRX, CANF, ASLN, and SXTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
8/11/2026
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/28/2026
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
7/10/2026
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/2/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00 ➝ $8.00
6/25/2026
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
$12M0.10N/AN/A($6.50) per share-0.09
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K3.61N/AN/A$1.76 per share1.27
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.14M0.94N/AN/A$2,468.59 per share0.00
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/AN/AN/AN/A$0.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$22.80N/AN/AN/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-$6.20MN/AN/AN/AN/AN/AN/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
-$51.06M-$1.10N/AN/AN/AN/A-1,899.61%-114.21%N/A

Latest VIRX, CANF, ASLN, and SXTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/1/2026Q4 2026
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/A$6.84N/A$6.8350N/A$0.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/AN/AN/AN/AN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
N/A
1.05
1.05
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.02
7.94
7.76
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
58.82%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
5.02%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
31.37%

Insider Ownership

CompanyInsider Ownership
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
4.69%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
3.95%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
10.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
ASLAN Pharmaceuticals Limited stock logo
ASLN
ASLAN Pharmaceuticals
302.04 million1.95 millionNo Data
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
8655,000N/ANot Optionable
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
90480,000459,000Not Optionable
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
2039.74 million35.50 millionNo Data

Recent News About These Companies

Calif. biotech company once worth $476M lays off every remaining employee
February 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/calif-biotech-company-once-worth-476m-lays-off-every-remaining-employee/ar-AA1yMmeD
Viracta Therapeutics Terminates Employees & Winds Down Operations
February 8, 2025  |  contractpharma.comC
Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Wind Down of Operations
February 6, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-02/64482743-viracta-therapeutics-inc-viracta-therapeutics-announces-wind-down-of-operations-399.htm
Viracta Therapeutics Shuts Down Operations, Lays Off All Staff
February 6, 2025  |  precisionmedicineonline.comP
Viracta Therapeutics terminates employees, to wind down operations
February 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/viracta-therapeutics-terminates-employees-to-wind-down-operations-1034318262
Viracta Therapeutics to cease operations and seek alternatives
February 5, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/viracta-therapeutics-to-cease-operations-and-seek-alternatives/ar-AA1yuqAR
Viracta Therapeutics Winds Down Operations, Terminates Employees
February 5, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/viracta-therapeutics-winds-down-operations-terminates-employees-b473adbb
Viracta Therapeutics hits end of the line, laying off all workers and winding down
February 5, 2025  |  fiercebiotech.comF
Viracta Therapeutics, Inc. Announces Employee Terminations and Wind Down of Operations
February 5, 2025  |  quiverquant.comQ
Viracta Therapeutics Announces Wind Down of Operations
February 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/05/3021635/0/en/viracta-therapeutics-announces-wind-down-of-operations.html
Why Did Viracta Therapeutics Inc (VIRX) Stock Tumble -46.67% to $0.08?
February 4, 2025  |  bovnews.comB
VIRX stock plunges to 52-week low, touches $0.08
February 3, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virx-stock-plunges-to-52-week-low-touches-008/ar-AA1ykUIq
Viracta Therapeutics to be delisted from Nasdaq
February 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/viracta-therapeutics-to-be-delisted-from-nasdaq/ar-AA1yk945
Viracta Therapeutics strikes deal to avoid default
January 25, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/viracta-therapeutics-strikes-deal-to-avoid-default/ar-AA1xRqjX
Viracta Therapeutics Inc (VIRX) Stock Trading Recap
January 10, 2025  |  bovnews.comB
VIRX’s Unexpected Surge: What’s Next?
January 6, 2025  |  bovnews.comB
Viracta Therapeutics Inc (VIRX) Stock Settles at $0.18: What’s Contributing to This Price Point?
January 3, 2025  |  bovnews.comB
Cash-strapped Viracta ends phase 2 study of lead cancer drug as it mulls remaining options
January 3, 2025  |  fiercebiotech.comF
Leerink Partners Issues Market Perform Rating for Viracta Therapeutics Inc (VIRX) Stock
December 30, 2024  |  bovnews.comB
ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls
December 27, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/servicetitan-initiated-viracta-downgraded-wall-143213358.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLAN Pharmaceuticals stock logo

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)
As of 09/4/2026

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$2.23 -0.12 (-5.11%)
As of 09/4/2026 04:00 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

China SXT Pharmaceuticals stock logo

China SXT Pharmaceuticals NASDAQ:SXTC

$2.23 +0.03 (+1.36%)
As of 09/4/2026 04:00 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Viracta Therapeutics stock logo

Viracta Therapeutics NASDAQ:VIRX

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas